News Search Results
Feb 27, 2024, 09:00 ET Ginkgo Biosecurity Launches Doha-Based Pathogen Monitoring Center, CUBE-D, Establishing Middle East Hub for Global Bioradar, at Qatar Free Zones
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Feb 21, 2024, 17:45 ET Global Mega Trends - Key Transformational Scenarios in 2040
MobilityAugmented Experiences - Total Sensory ImmersionAugmented Experiences - Mixed RealityBiotechnical Intervention - Synthetic Biology & Artificial DNABiotechnical Intervention - Gene Editing & Designer GeneticsBiotechnical Intervention - Diversification
More news about: Research and Markets
Feb 15, 2024, 18:30 ET Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
constitute an advertisement or medical advice. *1 ACCEL™ technology and convertibleCAR®: ACCEL™ technology is based on a synthetic biology approach that utilizes the binding of an engineered protein ligand to an orthogonal engineered receptor which forms the extracellular domain of
More news about: ASTELLAS PHARMA INC.
Feb 15, 2024, 07:02 ET Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Feb 13, 2024, 16:01 ET First Bight Ventures-Founded Accelerator Adds New Executive Director to its Management Team
Feb. 13, 2024 /PRNewswire/ -- BioWell, a nonprofit accelerator aimed at early-stage synthetic biology startups and the advancement of the bioeconomy, which was founded by Houston-based venture capital group First
More news about: First Bight Ventures
Feb 13, 2024, 10:21 ET New England Biolabs® Launches NEBNext® Enzymatic 5hmC-seq Kit, for enzyme-based 5hmC detection at single-base resolution
NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key
More news about: New England Biolabs, Inc.
Feb 13, 2024, 08:00 ET Molecular Assemblies Announces the Appointment of Two Industry Leaders to Its Commercial-Technology Advisory Board
following roles: Chief Scientific Officer at The Allen Institute, Chief Technology Officer at Synthetic Genomics, Inc., leading Genomics and Synthetic Biology R&D at Invitrogen/Life Technologies (now Thermo Fisher Scientific), and R&D positions at Genicon Sciences, Trega Biosciences, Hybritech,
More news about: Molecular Assemblies, Inc.
Feb 13, 2024, 07:01 ET House Select Committee Tours Ginkgo Bioworks, Previews Biofab1, Ginkgo's New Integrated Data Generation Facility Set to Launch in 2025
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Feb 07, 2024, 09:00 ET Complete Genomics and seqWell Announce Codevelopment Partnership at AGBT
workflow solutions, the companies aim to shorten sequencing turnaround times and increase throughput, particularly benefiting applications in synthetic biology, low-pass genomic screening, and environmental surveillance studies such as wastewater viral monitoring. "Next-generation sequencing customers
More news about: Complete Genomics
Feb 06, 2024, 09:00 ET Volta Labs and Integrated DNA Technologies Partner to Advance Target Enrichment Workflows
oligo manufacturer to a genomics solutions provider supporting key application areas such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Disclaimer: RUO — For research use only. Not for use in diagnostic procedures. Unless otherwise
More news about: Volta Labs Inc.
Feb 05, 2024, 10:00 ET New England Biolabs® to Celebrate 15 years of Innovation with NEBNext® Next Generation Sequencing Sample Preparation at AGBT 2024
NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key
More news about: New England Biolabs, Inc.
Feb 05, 2024, 08:30 ET Volta Labs and Watchmaker Genomics Partner to Simplify and Optimize NGS Library Prep
requirements of high-growth clinical genomics applications. Watchmaker's product portfolio includes enzymes and kits for next-generation sequencing, synthetic biology, and molecular diagnostics. For the latest news and updates, find us on
More news about: Volta Labs Inc.
Feb 01, 2024, 13:15 ET Global Molecular Biology Enzymes and Kits & Reagents Market Forecast to 2030
Polymerase Chain Reaction (PCR)SequencingCloningEpigeneticsRestriction DigestionSynthetic BiologyOthersCrucial Insights on End Users and Their Impacts Academic and Research InstitutesPharmaceutical
More news about: Research and Markets
Feb 01, 2024, 07:00 ET Bioluminescent Plants Are Now Even Brighter: Light Bio to Begin Selling Firefly Petunias to Consumers with USDA Approval
Idaho, Feb. 1, 2024 /PRNewswire/ -- Light Bio, an innovative synthetic biology startup, today announced that it is beginning to sell its groundbreaking bioluminescent petunias in the United States.
More news about: Light Bio
Jan 31, 2024, 12:00 ET UPSIDE Foods Appoints Veteran Cleantech Finance Leader as Chief Financial Officer and Promotes SVP to Chief Supply Chain & Manufacturing Officer
banking, and private equity, Hux has garnered substantial experience across disruptive industries, including clean technology, clean energy, and synthetic biology, and has led and advised on over $85 billion of financing and M&A transactions. Before joining UPSIDE,
More news about: UPSIDE Foods
Jan 31, 2024, 07:00 ET Phytolon and Ginkgo Bioworks Successfully Achieve First Milestone to Produce Vibrant Natural Food Colors via Two Producing Strains
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Jan 29, 2024, 09:17 ET First Patient Enrolled in Rise Therapeutics' Rheumatoid Arthritis Clinical Trial
disease severity and using a variety of key biomarker and pharmacodynamic assessments. About R-2487R-2487 is a synthetic biology-based immunotherapy being developed to treat autoimmune disease. R-2487 works by inducing bystander tolerance via evolution of specific immune
More news about: Rise Therapeutics
Jan 29, 2024, 09:00 ET Asimov launches LV Edge Packaging System to optimize lentivirus production
BOSTON, Jan. 29, 2024 /PRNewswire/ -- Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of their LV Edge Packaging System, which improves the
More news about: Asimov
Jan 26, 2024, 06:15 ET Synthetic Biology Technology Market Report 2024 - Top Suppliers and Growth Forecast to 2028
Emerging Trends/Technologies in the Synthetic Biology Market Prime EditingAI in Synthetic BiologyDNA Data StorageDo-it-yourself Synthetic Biology CommunityChapter 6 Sustainability in Synthetic Biology Market: An ESG Perspective
More news about: Research and Markets
Jan 24, 2024, 07:00 ET Ayana Bio and Wooree Green Science Partner to Develop Plant-Cell Derived Saffron for Health & Wellness Products
bring the power of plant bioactives to the mass market at scale. Ayana Bio has partnered with the global leader in synthetic biology, Ginkgo Bioworks, to select, optimize and scale plant cell-cultivated ingredients. Ayana Bio is backed by prestigious
More news about: Ayana Bio
Jan 15, 2024, 14:30 ET Global Antibody Fragments Market Research Report 2023: Market to Reach $9.6 Billion by 2028 - Increasing Investments in Biopharmaceuticals Driving Growth
gene editing, and high-throughput screening enhance antibody fragment development.Emerging biotechnology platforms like CRISPR-Cas9 and synthetic biology improve production and functionality.Antibody fragments are engineered for improved pharmacokinetics and reduced immunogenicity.Segmental
More news about: Research and Markets
Jan 15, 2024, 07:00 ET Concentric by Ginkgo and Illumina collaborate to deploy biosurveillance technologies around the world
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks
Jan 11, 2024, 09:00 ET Sequentify Awarded Grant by Israel Innovation Authority for Infectious Disease Sequencing Panel
Sequentify: Founded in 2021 as a Weizmann Institute of Science spinoff, Sequentify provides a technology that is based on tools from the synthetic biology and AI software worlds for targeted DNA sequencing applications such as cancer diagnostics, carrier screening, COVID-19 surveillance and other
More news about: Sequentify
Jan 11, 2024, 06:00 ET Eleven Therapeutics Welcomes Dr. Paloma H Giangrande as Chief Technology Officer
Eleven Therapeutics: Eleven Therapeutics is at the forefront of mRNA therapeutics innovation, harnessing combinatorial chemistry, synthetic biology, and artificial intelligence to develop next-generation therapies. The company's pipeline includes extended-release mRNA therapeutics (xRNA) targeting
More news about: Eleven Therapeutics
Jan 10, 2024, 07:35 ET Ginkgo Bioworks Provides Business Updates at J.P. Morgan Healthcare Conference
and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry,
More news about: Ginkgo Bioworks